Association between immune-related adverse events and clinical outcomes to PD-1/PD-L1 blockade in small cell lung cancer

Background null The development of immune-related adverse events (irAEs) has been associated with improved efficacy of immune checkpoint inhibitors in patients with urothelial cancer, melanoma, and non-small cell lung cancer. Whether this association exists in patients with small cell lung cancer (SCLC) is currently unknown. null null null Methods null We conducted a multicenter retrospective study to evaluate the relationship between irAEs and...